Zoom Logo

IMMU - Shared screen with speaker view
Luis Zapata
33:24
From an evolutionary point, Wouldn’t severe covid19 leading to early hospitalisation and potentially inability to spread would be an en end point for variants increasing severity?
Luis Zapata
33:50
great work btw!
Meghna Verma
51:22
Great work on the use of multiscale model for COVID. What type of data was used to calibrate the agent based model? Looking forward to the rest of the talks in this session!
Paul Macklin
52:03
Hi, Meghna! I can give part of that answer, and Ashlee, Courtney, Morgan, Adrianne and others can also join in
Paul Macklin
52:19
We're at the stage where we're trying to get the main mechanisms built in.
Paul Macklin
52:42
So we're not quite at full calibration stage yet -- needa model to calibrate first!
Paul Macklin
52:57
But we are working with physical and biological constraints
Paul Macklin
53:12
estimating time scales of processes, constraining model to evolve at right time scale, spatial scale, etc.
Paul Macklin
53:37
and many parameters can be pinned down within order of magnitude for future zeroing in on the calibration
Paul Macklin
54:12
And we also have a nice perspective from Penny: for the default model settings, the patient recovers. And this places constraints on viral load and immune activation.
Paul Macklin
55:12
We're also looking towards high-throughput investigations on HPC to explore parameter space and see how it maps to trajectory space. WHat are parameter regimes that give "patients" who recover? Can we work in that constrained subset to find better values?Same in servere cases, etc.
Meghna Verma
55:57
Thanks, Paul! Certainly. That's helpful to know, thank you for the detailed answer:)
Paul Macklin
01:32:31
I just love these virtual cohorts, Morgan and Adrianne
Morgan Craig
01:33:31
Me too, they’ve been teaching us a lot in many projects
Zython Paul Lachica_UP Mindanao
01:44:48
Wow! Very informative talk!!! So much learnings!
Meghna Verma
01:44:50
Great talk, Adrianne! How are severe patients characterized? Is it based on number of T cells/IL6?
Paul Macklin
01:45:32
Just phenomenal work.
Krutika Patidar
01:45:52
Amazing talk!
Courtney Davis
01:46:22
Great job to all the speakers!
Zython Paul Lachica_UP Mindanao
01:46:31
This "classification" of disease severity can be very useful.